CGEM20261016C19
CGEM Oct 16 2026 19.00 Call (CGEM261016C00019000)
option OPRA

cullinan oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. sourced from the cullinan dry lab as well as external collaborators, cullinan's assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.